Stroke drug sits at the center of this dementia and brain health question.
The drug is alteplase, a clot-dissolving medication that has been the only FDA-approved treatment for acute ischemic stroke for nearly three decades. If a patient suffering an ischemic stroke receives alteplase within the approved window, it improves outcomes in approximately one in three treated patients. But the clock is unforgiving. Beyond 4.5 hours from symptom onset, thrombolysis significantly increases the risk of symptomatic intracranial hemorrhage, with an odds ratio of 3.75, and raises the risk of death at three to six months. That narrow window between rescue and catastrophe is not a rough guideline — it is a biological deadline written into the chemistry of dying brain tissue.
In March 2025, the FDA approved tenecteplase, sold as TNKase and manufactured by Genentech, marking the first new stroke medication approved in nearly 30 years. Unlike alteplase’s hour-long infusion, tenecteplase is delivered as a single five-second IV bolus, a difference that could reshape emergency stroke care from rural hospitals to mobile stroke units. Yet the time constraint remains. Both drugs carry FDA labeling recommending initiation within three hours of symptom onset, and the science supporting use out to 4.5 hours, while well-established, remains technically off-label in the United States. This article explains what these drugs do to a blood clot in real time, why every minute of delay costs measurable brain function, who actually receives treatment and who does not, what the drugs cost, and where research is pushing the treatment window beyond what was thought possible even five years ago.
Table of Contents
- Why Must the Stroke Drug Be Given Within 4.5 Hours — and What Happens When It’s Too Late?
- How Alteplase and Tenecteplase Actually Work — and Where Each Falls Short
- The Treatment Gap — Why Fewer Than One in Four Eligible Patients Get the Drug
- What Tenecteplase Means for Emergency Stroke Care Going Forward
- The Staggering Cost of Stroke Treatment — and Why Hospitals Lose Money Saving Lives
- Pushing Past 4.5 Hours — The Emerging Science of Late-Window Thrombolysis
- What the Next Decade of Stroke Treatment Looks Like
- Conclusion
- Frequently Asked Questions
Why Must the Stroke Drug Be Given Within 4.5 Hours — and What Happens When It’s Too Late?
An ischemic stroke occurs when a blood clot blocks an artery supplying the brain. From the moment blood flow stops, approximately 1.9 million neurons die every minute. Alteplase and tenecteplase are tissue plasminogen activators — they convert plasminogen into plasmin, which dissolves the fibrin mesh holding a clot together. Administer the drug early enough and blood flow resumes before permanent damage sets in. wait too long and the drug does not simply fail to work — it actively becomes dangerous. Brain tissue that has been starved of oxygen for hours becomes fragile. Forcing blood back through damaged vessels at that point causes bleeding into the brain itself. A study published in the AHA journal Stroke found that thrombolysis beyond 4.5 hours carries an odds ratio of 3.75 for symptomatic intracranial hemorrhage and 1.18 for death at three to six months.
The landmark ECASS III trial, published in the New England Journal of Medicine, is the reason doctors treat between three and 4.5 hours at all. That trial demonstrated a seven percent absolute increase in good functional outcomes — 52.4 percent of patients treated in the 3-to-4.5-hour window achieved a modified Rankin Scale score of 0 to 1 at 90 days, compared to 45.2 percent of those given placebo. Seven percent may sound modest on paper. In practice, for a condition that strikes 795,000 Americans every year, it translates to tens of thousands of people who walk out of rehabilitation instead of requiring permanent assisted care. The critical nuance is that the FDA-approved window for alteplase is actually within three hours, not 4.5. Treatment between three and 4.5 hours is supported by AHA/ASA guidelines and is standard practice, but it remains technically off-label in the United States, even though more than fifteen European countries have approved it in that extended window. This matters because some smaller hospitals, wary of liability, may hesitate at the three-hour mark. Patients and families should understand that guideline-supported treatment at 3.5 or 4 hours is well-evidenced — but that every additional minute of delay narrows the benefit and widens the risk.
How Alteplase and Tenecteplase Actually Work — and Where Each Falls Short
Alteplase is administered intravenously at a dose of 0.9 milligrams per kilogram, with a maximum of 90 milligrams. Ten percent is given as an initial bolus, and the remainder is infused over sixty minutes. The drug‘s half-life is roughly four minutes, meaning it clears the bloodstream fast but must be continuously dripped to maintain its effect. This protocol requires an IV pump, continuous monitoring, and a nursing team comfortable with the dosing math. It works, but it is not simple, and in the chaos of a stroke code at a community hospital at two in the morning, complexity is the enemy of speed. Tenecteplase changes the logistics dramatically. It is a single weight-based IV bolus of 0.25 milligrams per kilogram, pushed over five seconds. Its half-life is 22 minutes — more than five times longer than alteplase — meaning one push sustains therapeutic drug levels without an infusion.
The AcT trial demonstrated that tenecteplase was non-inferior to alteplase, with statistically significant improvement in excellent functional outcomes and higher recanalization rates. Safety profiles, including rates of symptomatic intracranial hemorrhage and death, were comparable between the two drugs. The ATTEST-2 trial published in The Lancet Neurology confirmed these findings. However, neither drug works for every stroke. Roughly 13 percent of strokes are hemorrhagic — caused by bleeding rather than a clot — and giving a clot-dissolving agent to someone already bleeding in the brain is potentially fatal. This is why imaging is non-negotiable before treatment. A CT scan must confirm ischemic stroke and rule out hemorrhage before either drug is administered. Additionally, patients on certain anticoagulants, those with very high blood pressure, or those with recent major surgery may be excluded from treatment. The drug’s power to dissolve clots is indiscriminate, which means it can reopen surgical wounds or worsen existing bleeding elsewhere in the body.
The Treatment Gap — Why Fewer Than One in Four Eligible Patients Get the Drug
Here is perhaps the most troubling statistic in stroke medicine: only about 10 to 23 percent of eligible stroke patients receive thrombolytic therapy. From 2015 to 2019, IV thrombolysis use grew by 60.3 percent, reaching 22.9 percent among patients treated within 4.5 hours. That improvement is real, but it still means roughly three out of four people who could benefit from the drug never receive it. The reasons are layered. Many patients do not recognize stroke symptoms quickly enough. The acronym FAST — face drooping, arm weakness, speech difficulty, time to call 911 — has improved public awareness, but a significant portion of stroke patients either live alone, are asleep when the stroke begins, or mistake their symptoms for something less urgent. A 68-year-old man who wakes up with a numb hand and slurred speech at 6 a.m.
may assume he slept on his arm and wait until his wife wakes up to mention it. By the time he reaches the emergency department, two or three hours have already passed. If the hospital is a small facility without neurology coverage and he needs to be transferred to a stroke center, the clock may run out entirely. Hospital-level barriers compound the problem. Not every emergency department stocks alteplase. Not every ER physician is comfortable initiating thrombolysis without a neurologist on site, even though telestroke programs have made remote consultation available. Rural hospitals face the starkest version of this problem — longer transport times, fewer specialists, and older patient populations with higher stroke rates. Tenecteplase’s single-bolus administration could meaningfully help here, because a drug that can be given in five seconds by an emergency physician before transferring the patient is far more practical than one requiring a sixty-minute infusion that must begin and continue during an ambulance ride.
What Tenecteplase Means for Emergency Stroke Care Going Forward
The FDA approval of tenecteplase in March 2025 was not a breakthrough in the sense of a new mechanism of action — it is the same class of drug as alteplase. The breakthrough is operational. Consider the difference between a 60-minute drip and a 5-second push in three scenarios. First, a mobile stroke unit — essentially an ambulance with a CT scanner — can now diagnose and fully treat a patient on the street. With alteplase, they could start the bolus but had to continue the infusion during transport. With tenecteplase, treatment is complete before the ambulance moves. Second, a rural ER that would normally need to transfer a stroke patient can give the full dose of tenecteplase and then arrange transport, rather than trying to manage an infusion during a helicopter ride. Third, in mass casualty or resource-constrained situations, a drug that does not require a pump or continuous monitoring frees nursing staff to care for other patients.
The tradeoff is familiarity. Alteplase has been the standard of care since 1996. Every stroke protocol, every nursing competency checklist, every malpractice precedent is built around it. Switching to tenecteplase requires updating protocols, retraining staff, and restocking pharmacy inventories. Some institutions will move quickly; others will lag for months or years. During that transition, there will be hospitals that stock both drugs, hospitals that stock only one, and confusion about which to reach for. For patients, the practical advice is straightforward: do not ask for a specific drug. Ask for the fastest door-to-needle time the hospital can deliver. The specific thrombolytic matters far less than the minutes on the clock.
The Staggering Cost of Stroke Treatment — and Why Hospitals Lose Money Saving Lives
A single 100-milligram vial of alteplase costs approximately $8,604 at retail pharmacy pricing. Between 2005 and 2014, the cost of alteplase rose by 111 percent — from $2,867 to $6,153 — while Medicare reimbursement for stroke thrombolysis rose only 8 percent over the same period. That gap means many hospitals, particularly smaller community facilities, lose money every time they administer the drug. Despite this, thrombolysis remains cost-effective to society when accounting for the long-term costs of stroke disability — nursing home care, lost productivity, ongoing rehabilitation, and caregiver burden. This financial pressure creates a perverse dynamic.
The hospitals most needed to provide rapid stroke treatment — small, rural, underresourced facilities serving aging populations — are the ones least able to absorb the cost. Some have removed alteplase from their formularies entirely, relying instead on transfer agreements with larger stroke centers. The result is added transport time, which directly reduces the chances that a patient will be treated within the window. Whether tenecteplase will be priced comparably to alteplase, cheaper, or more expensive remains an important question. A lower-cost thrombolytic with easier administration could be the single most impactful change in stroke care access in a generation — or, if priced at a premium, it could simply replicate the existing problem with a newer label.
Pushing Past 4.5 Hours — The Emerging Science of Late-Window Thrombolysis
For decades, 4.5 hours was treated as an absolute wall. Recent research is finding doors in that wall — not for every patient, but for carefully selected ones. A 2024 study published in the New England Journal of Medicine examined tenecteplase for ischemic stroke between 4.5 and 24 hours after symptom onset in patients who were not candidates for mechanical thrombectomy. Using advanced imaging to identify patients with salvageable brain tissue, the study showed potential benefit in extending treatment far beyond what was previously considered safe.
Similarly, research into MRI-guided thrombolysis has found that alteplase administered between 4.5 and 12 hours can be safe and effective in selected patients with DWI/T2WI mismatch — a neuroimaging signature indicating that ischemic tissue has not yet progressed to irreversible infarction. This does not mean the 4.5-hour window is obsolete. It means that for patients who arrive late or whose stroke onset time is unknown, advanced imaging may identify a subset who can still benefit. The key distinction is that early treatment works based on time alone, while late treatment requires imaging proof that brain tissue is still viable. Time-based treatment is fast and universal; imaging-based treatment is slower, requires specialized equipment, and is available only at comprehensive stroke centers.
What the Next Decade of Stroke Treatment Looks Like
The convergence of tenecteplase’s simpler dosing, expanding mobile stroke unit programs, and imaging-guided late-window treatment points toward a future where far more than 23 percent of eligible patients receive thrombolysis. Artificial intelligence is already being deployed to read CT scans faster and flag large vessel occlusions in real time, potentially shaving minutes off the decision-to-treat timeline. Telestroke networks continue to expand, putting neurologists on screen in hospitals that could never recruit one in person. But the most important variable in stroke treatment has not changed and is unlikely to change: public awareness that stroke is a time-dependent emergency requiring an immediate 911 call.
No drug — no matter how easy to administer or how wide its treatment window — can help a patient who is sitting at home hoping the numbness in their left side goes away on its own. The gap between what medicine can do and what patients actually receive remains the central tragedy of stroke care. Closing that gap is not a pharmacological problem. It is an educational one, a logistical one, and in many communities, an economic one.
Conclusion
Alteplase and now tenecteplase represent one of the clearest examples in modern medicine of a treatment that works extraordinarily well within its window and becomes dangerous beyond it. The 4.5-hour threshold is not arbitrary — it reflects the point at which the risk of brain hemorrhage begins to overtake the benefit of clot dissolution. Within that window, thrombolysis improves outcomes in roughly one in three patients. Outside it, the drug that could have saved a life can end one. Tenecteplase’s approval in 2025 does not change the biology of ischemic brain injury, but it removes one of the most significant practical barriers to rapid treatment: the complexity of administration.
For anyone concerned about brain health — whether because of personal risk factors, family history, or a caregiving role — the actionable takeaway is blunt. Learn the signs of stroke. Call 911 immediately, not after waiting to see if symptoms improve. Note the exact time symptoms began, because that timestamp determines what treatment is possible. Every minute matters, and the difference between a good outcome and a devastating one is often decided not in the hospital, but in the first moments after something goes wrong at home.
Frequently Asked Questions
What is the difference between alteplase and tenecteplase for stroke?
Both are clot-dissolving drugs in the same class, but they differ in administration. Alteplase requires a 60-minute IV infusion, while tenecteplase is a single 5-second IV bolus. Tenecteplase was FDA-approved for acute ischemic stroke in March 2025 and showed non-inferior results with potentially higher recanalization rates in clinical trials. Both carry FDA labeling recommending initiation within 3 hours of symptom onset.
Why is the treatment window 4.5 hours and not longer?
Beyond 4.5 hours, clinical data shows the risk of symptomatic intracranial hemorrhage increases sharply (OR 3.75) and the risk of death at 3 to 6 months also rises. The ECASS III trial established that treatment between 3 and 4.5 hours still provides net benefit, but beyond that point, damaged brain tissue is too fragile to safely restore blood flow with thrombolytics in most patients. However, imaging-guided treatment beyond 4.5 hours may still benefit carefully selected patients.
Can stroke be treated after 4.5 hours?
In some cases, yes. A 2024 NEJM study showed potential benefit for tenecteplase between 4.5 and 24 hours in imaging-selected patients. MRI-guided alteplase has also shown promise between 4.5 and 12 hours. These extended-window treatments require advanced brain imaging to confirm that salvageable tissue remains and are only available at comprehensive stroke centers.
Why do so few stroke patients receive the clot-dissolving drug?
Only about 10 to 23 percent of eligible patients receive thrombolysis. Delays stem from patients not recognizing symptoms quickly enough, long transport times to stroke-capable hospitals, hospitals lacking the drug or specialist support, and the narrow treatment window itself. Tenecteplase’s simpler administration may help improve these numbers, particularly in rural settings.
How much does stroke thrombolysis cost?
A 100 mg vial of alteplase costs approximately $8,604 at retail pricing. The cost rose 111 percent between 2005 and 2014, while Medicare reimbursement rose only 8 percent over the same period. Despite the high per-dose cost, thrombolysis is considered cost-effective when measured against the long-term expenses of stroke disability.
What are the signs of stroke that should prompt an immediate 911 call?
Use the FAST acronym: Face drooping on one side, Arm weakness or inability to raise both arms evenly, Speech that is slurred or difficult to understand, and Time to call 911 immediately. Other symptoms can include sudden severe headache, vision loss, confusion, or difficulty walking. Note the exact time symptoms began — this information directly determines what treatments are available.
You Might Also Like
- The Drug Given to Premature Babies’ Lungs That Saves Thousands of Lives
- Trigeminal Neuralgia: The Electric Face Pain Drug That Actually Works
- The Ulcerative Colitis Drug Achieving Remission 3x Faster Than Standard Therapy
For more, see Alzheimer’s Association.
